Navigation Links
Chemo Combo May Help Stave Off Pancreatic Cancer Death
Date:5/11/2011

By Maureen Salamon
HealthDay Reporter

WEDNESDAY, May 11 (HealthDay News) -- A four-drug chemotherapy regimen for deadly pancreatic cancer nearly doubled patients' survival time compared to standard chemotherapy, a new study suggests.

In late-stage trials, French researchers split a group of 342 patients with advanced pancreatic adenocarcinoma, the most common form of the disease, into two groups. Half received gemcitabine, the standard treatment, while the rest received FOLFIRINOX, a four-drug combination of oxaliplatin, irinotecan, leucovorin and fluorouracil.

The median survival time improved from 6.8 months for those in the gemcitabine group to 11.1 months in the FOLFIRINOX group, according to the study, which is published in the May 12 issue of the New England Journal of Medicine. Those in the combination group did suffer greater side effects from treatment, however.

"We explain to the patients the advantages and toxicities of both regimens," said study author Dr. Thierry Conroy, a professor of medical oncology at Nancy University and Centre Alexis Vautrin in Nancy, France. "The FOLFIRINOX regimen was able to stabilize patients longer with improved quality of life and delay degradation of quality of life. Unfortunately, it is still a palliative treatment but able to save months, and sometimes years of life."

Pancreatic adenocarcinoma was the fourth leading cause of cancer deaths in the United States in 2010, the study said, and the five-year survival rate is only 6 percent in both the United States and Europe.

Study participants, whose average age was 61, were still fully active and able to carry out daily activities, and sicker patients were not eligible. The trial was conducted at 15 centers in France during the second phase of the trial and expanded to 48 centers during the third phase of the trial.

Patients discontinued the study at their request or if they experienced unacceptable toxic effects -- which included diarrhea, low blood cell counts and sensory neuropathy -- or evidence of disease progression. One patient from each group died from treatment-related causes, and 273 of the 342 patients had died by the end of the median follow-up period of 26 months.

Dr. Alberto Montero, an assistant professor of medicine at Sylvester Comprehensive Care Center at University of Miami Miller School of Medicine, said the results were "remarkable" because the FOLFIRINOX group experienced such an improved survival rate.

Montero cautioned, however, that a small minority of patients with pancreatic adenocarcinoma match the condition of patients in the study, who were still conducting normal daily activities. Even newly diagnosed patients are often extremely ill, he said, and might not be able to tolerate the combination drugs' toxic effects.

"To see a doubling in survival is impressive," said Montero, also a medical oncologist. "For many reasons, this cancer is very resistant to chemotherapy. I think this trial is a first step."

More information

The U.S. National Institutes of Health has more on pancreatic cancer.

SOURCES: Thierry Conroy, M.D., professor, medical oncology, Nancy University and Centre Alexis Vautrin, Nancy, France; Alberto J. Montero, M.D., assistant professor, medicine, Sylvester Comprehensive Cancer Care Center, University of Miami Miller School of Medicine; May 12, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Genetic information may help predict likelihood of survival following chemotherapy for breast cancer
2. Genomic test shows promise as chemotherapy response, survival predictor for women with breast cancer
3. Most Leukemia Patients Recover From Chemo Brain After Transplant: Study
4. Gene expression predicts chemotherapy sensitivity of triple-negative breast cancer
5. Most patients recover from chemo-brain by 5 years after stem cell transplant
6. RxPONDER trial will evaluate whether gene expression test can drive chemotherapy choice
7. Managing Chemoradiation Side Effects May Prolong Survival
8. Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer
9. Minimizing side effects from chemoradiation could help brain cancer patients live longer
10. Immune system may guide chemotherapy for breast cancer
11. New approach to leukemia chemotherapy -- is a cure in sight?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Chemo Combo May Help Stave Off Pancreatic Cancer Death
(Date:8/22/2017)... ... August 22, 2017 , ... “Wilderness Voices”: a collection ... travel. “Wilderness Voices” is the creation of published author, Martha McKown, an ordained ... was inspired as a very young child when her older sisters studied High School ...
(Date:8/22/2017)... Raleigh, North Carolina (PRWEB) , ... August 22, ... ... senior strategic advisor. Mr. Stewart is the Founder and Managing Member for t4 ... elements that have become critical to his definition of “success”: physician leadership development, ...
(Date:8/21/2017)... ... August 22, 2017 , ... PracticeMatch, a company that provides online resources ... physicians and advanced practitioners like nurse practitioners and physician assistants , ... November of this year. The online career fairs will allow job seekers to connect ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... FCPX LUT ... Editors can quickly and easily add washed color grades to footage. A LUT ... LUT changes every pixel’s color to the corresponding color indicated by the table. This ...
(Date:8/21/2017)... ... August 21, 2017 , ... ... involvement program serving the people of Michigan. The new initiative fundraises for the ... at the very forefront of animal protection and welfare by addressing the root ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
(Date:7/28/2017)... Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today announced financial ... 2017, and updated its financial outlook for fiscal 2017. ... fiscal third quarter, Hill-Rom reported earnings of $0.09 per ... the prior-year period. These results reflect after-tax special items, ... related to the non-cash write-down of assets associated with ...
(Date:7/26/2017)... Colo. , July 26, 2017 E.I. ... Guttridge and the Bimini SharkLab to custom design the worlds ... images of sharks in their native habitat. In preparation ... Discovery Channel,s Shark Week, Dr. Guttridge approached EIMI ... take pregnancy diagnosis directly to hammerhead sharks underwater. ...
Breaking Medicine Technology: